GW Pharmaceuticals (GWPH) Stock Lower After Results of First Sativex Phase 3 Trials

Shares of GW Pharmaceuticals plc (GWPH) were trading down -9.50 or -13.36 percent to $61.56 per share in this morning’s premarket, after the company announced early this morning the results of the first of three its investigational product, Sativex in Phase 3 trials. The company also released an update on its development program for Epidiolex, Read the full article... Read the rest of GW Pharmaceuticals (GWPH) Stock Lower After Results of First Sativex Phase 3 Trials at InvestorGuide.com .